{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:Q76LX8",
      "entity_text" : "ADAMTS13",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uniprot:P26651",
      "entity_text" : "TTP",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "XREF_BIBR In more than 95% of the patients, TTP is caused by the presence of anti-ADAMTS13 autoantibodies (immune mediated TTP) that inhibit ADAMTS13 activity or accelerate its clearance from circulation.",
  "reading_complete" : "2020-08-03T13:13:15Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-03T13:11:57Z",
  "trigger" : "inhibit",
  "evidence" : [ "TTP) that inhibit ADAMTS13" ],
  "pmc_id" : "6524854",
  "score" : 0
}